Immune checkpoint inhibitors in patients with pretreated Hodgkin Ês lymphoma: a Korean single-center, retrospective study.

Conclusion: In this study, pembrolizumab and nivolumab both demonstrated clinical efficacy and tolerability in patients with cHL who failed previous chemotherapy or ASCT. PMID: 32595170 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/32595170?dopt=Abstract

Source: Blood Research - July 2, 2020 Category: Hematology Tags: Blood Res Source Type: research